MX2020003001A - Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. - Google Patents

Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.

Info

Publication number
MX2020003001A
MX2020003001A MX2020003001A MX2020003001A MX2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A
Authority
MX
Mexico
Prior art keywords
water
roflumilast
miscible
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
MX2020003001A
Other languages
English (en)
Inventor
David W Osborne
Original Assignee
Arcutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcutis Inc filed Critical Arcutis Inc
Publication of MX2020003001A publication Critical patent/MX2020003001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La baja solubilidad acuosa de roflumilast en preparaciones parenterales y emulsiones tópicas, suspensiones, geles o soluciones se puede mejorar al incluir una mezcla de solventes miscibles en agua en la composición farmacéutica; la mezcla de solventes miscibles en agua puede incluir dietilen glicol monoetil éter (Nombre comercial Transcutol(r); abreviado DEGEE) y agua; la relación de dietilen glicol monoetil éter a agua es de 1:10 a 20:1; la composición resultante tiene biodisponibilidad y eficacia mejoradas y se puede utilizar para inhibir la fosfodiesterasa 4 en un paciente en necesidad de dicho tratamiento.
MX2020003001A 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. MX2020003001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,900 US11534493B2 (en) 2017-09-22 2017-09-22 Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
PCT/US2018/051691 WO2019060379A1 (en) 2017-09-22 2018-09-19 PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE SOLVENTS MISCIBLE TO WATER

Publications (1)

Publication Number Publication Date
MX2020003001A true MX2020003001A (es) 2020-09-28

Family

ID=63794682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003001A MX2020003001A (es) 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.

Country Status (12)

Country Link
US (2) US11534493B2 (es)
EP (2) EP3684334B1 (es)
JP (3) JP7191944B2 (es)
KR (1) KR20200058402A (es)
CN (1) CN111107836A (es)
AU (1) AU2018337752B2 (es)
BR (1) BR112020005421A8 (es)
CA (1) CA3076002A1 (es)
EA (1) EA202090813A1 (es)
IL (1) IL273376B1 (es)
MX (1) MX2020003001A (es)
WO (1) WO2019060379A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) * 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
AU2019281888B2 (en) * 2018-06-04 2024-05-02 Arcutis Biotherapeutics Inc Method and formulation for improving roflumilast skin penetration lag time
EP4041211A4 (en) * 2019-10-11 2023-09-06 Zenvision Pharma LLP IMPROVED TOPICAL COMPOSITION OF COLCHICINE
IL295172A (en) * 2020-01-31 2022-09-01 Arcutis Biotherapeutics Inc Composition of topical roflumilest with improved administration and half-life in plasma
WO2022169615A1 (en) * 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509099A (ja) * 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9618974D0 (en) * 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1511516B1 (en) 2002-05-28 2008-12-17 Nycomed GmbH Topically applicable pharmaceutical preparation
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
PT1670433E (pt) * 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
JPWO2006041121A1 (ja) 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
CN101541321A (zh) * 2006-09-06 2009-09-23 Isw集团公司 局部用组合物
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
JP2014509655A (ja) 2011-03-31 2014-04-21 アコルダ セラピュティクス インコーポレーテッド 鼻腔内ベンゾジアゼピン薬剤学的組成物
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
PT2704703T (pt) * 2011-05-03 2019-10-25 Aponia Laboratories Inc Composições transdermais de ibuprofeno e seus métodos de utilização.
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
JP6426624B2 (ja) 2013-01-28 2018-11-21 インコゼン・セラピューティクス・プライベート・リミテッド ロフルミラストｎ−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
US20140275265A1 (en) * 2013-03-12 2014-09-18 Core Products International, Inc. Therapeutic cream for application to skin
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
MX2017002438A (es) * 2014-08-27 2017-05-23 Abbvie Inc Formulacion topica.
SG10202112628UA (en) 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
CN109310624A (zh) * 2016-06-15 2019-02-05 托伦特药物有限公司 阿普斯特的局部组合物
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast

Also Published As

Publication number Publication date
EA202090813A1 (ru) 2020-08-14
IL273376B1 (en) 2024-03-01
CA3076002A1 (en) 2019-03-28
JP7191944B2 (ja) 2022-12-19
US20230091358A1 (en) 2023-03-23
CN111107836A (zh) 2020-05-05
KR20200058402A (ko) 2020-05-27
US20190091333A1 (en) 2019-03-28
EP4316590A3 (en) 2024-05-01
AU2018337752A1 (en) 2020-04-09
US11534493B2 (en) 2022-12-27
EP4316590A2 (en) 2024-02-07
EP3684334B1 (en) 2023-12-06
JP2024028911A (ja) 2024-03-05
WO2019060379A1 (en) 2019-03-28
BR112020005421A8 (pt) 2022-12-13
JP2020534303A (ja) 2020-11-26
EP3684334C0 (en) 2023-12-06
BR112020005421A2 (pt) 2020-09-29
AU2018337752B2 (en) 2024-03-28
EP3684334A1 (en) 2020-07-29
IL273376A (en) 2020-05-31
JP2023027195A (ja) 2023-03-01
JP7402301B2 (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
MX2020003001A (es) Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
NO20081576L (no) Preparater og fremgangsmater for fremstilling av darlig vannloselige legemidler med okt stabilitet
WO2015120231A8 (en) Stable peptide formulations and methods for preparation
EA201600118A1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
TN2015000445A1 (en) Derivatives of dolastatin 10 and auristatins
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
MX357304B (es) Formulaciones inmunosupresoras.
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
AU2018320946B2 (en) Amantadine compositions, preparations thereof, and methods of use
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
GB2554008A (en) Stable liquid pharmaceutical compositions of bortezomib
WO2022031862A3 (en) Heteroaryl and heterocyclyl compounds
EA202090445A1 (ru) ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX2021014614A (es) Composiciones terapeuticas estables en solventes polares aproticos y metodos de elaboracion de las mismas.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX2019004576A (es) Composiciones farmaceuticas.
RU2017129736A (ru) Не окрашивающая гелевая композиция, содержащая нимесулид, для местного применения
WO2019166033A3 (zh) 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途